6533b81ffe1ef96bd12770e9

RESEARCH PRODUCT

Production of Adenosine by Ectonucleotidases: A Key Factor in Tumor Immunoescape

François GhiringhelliCédric RébéFanny ChalminFanny ChalminMélanie BruchardMélanie Bruchard

subject

AdenosineStromal cellArticle SubjectHealth Toxicology and Mutagenesislcsh:Biotechnologylcsh:MedicineAntineoplastic AgentsBiologyPharmacology5'-nucleotidaseDephosphorylationImmune systemNeoplasmslcsh:TP248.13-248.65GeneticsmedicineAnimalsHumansEctonucleotidaseMolecular Targeted Therapy5'-NucleotidaseMolecular BiologyImmune EvasionTumor microenvironmentlcsh:RGeneral MedicineAdenosineCancer cellCancer researchMolecular MedicineResearch ArticleBiotechnologymedicine.drug

description

It is now well known that tumor immunosurveillance contributes to the control of cancer growth. Many mechanisms can be used by cancer cells to avoid the antitumor immune response. One such mechanism relies on the capacity of cancer cells or more generally of the tumor microenvironment to generate adenosine, a major molecule involved in antitumor T cell response suppression. Adenosine is generated by the dephosphorylation of extracellular ATP released by dying tumor cells. The conversion of ATP into adenosine is mediated by ectonucleotidase molecules, namely, CD73 and CD39. These molecules are frequently expressed in the tumor bed by a wide range of cells including tumor cells, regulatory T cells, Th17 cells, myeloid cells, and stromal cells. Recent evidence suggests that targeting adenosine by inhibiting ectonucleotidases may restore the resident antitumor immune response or enhance the efficacy of antitumor therapies. This paper will underline the impact of adenosine and ectonucleotidases on the antitumor response.

10.1155/2012/473712https://doaj.org/article/85faef675c9a43ce8eb48ea4b520ec1c